Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATIVE RESEARCH & LICENSE AGREEMENT Dated August 13, 2007 Between ICAGEN, INC. and PFIZER INCCollaborative Research & License Agreement • November 5th, 2007 • Icagen Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH & LICENSE AGREEMENT is entered into as of August 13, 2007 (the “Effective Date”) by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 (“Pfizer”), and ICAGEN, INC. (“Icagen”), a Delaware corporation, having an office at 4222 Emperor Boulevard, Suite 350, Durham, North Carolina 27703.
THIRD AGREEMENT AND AMENDMENT TO THE COLLABORATIVE RESEARCH & LICENSE AGREEMENT July 20, 2011Collaborative Research & License Agreement • July 20th, 2011 • Icagen Inc • Pharmaceutical preparations
This Third Agreement and Amendment to the Collaborative Research & License Agreement (the “Third Amendment”) is dated as of the date hereof, between Icagen, Inc., a Delaware corporation with offices at 4222 Emperor Boulevard, Suite 350, Durham, North Carolina 27703 (“Icagen”), and Pfizer Inc., a Delaware corporation with offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”).
Pfizer Logo]Collaborative Research & License Agreement • August 13th, 2009 • Icagen Inc • Pharmaceutical preparations
ContractCollaborative Research & License Agreement • November 8th, 2006 • Lipid Sciences Inc/ • Biological products, (no disgnostic substances)
Portions of this agreement, marked by asterisks (***), have been omitted pursuant to a request for confidential treatment. The omitted information has been filed separately with the Securities and Exchange Commission
